Market capitalization | €116.97m |
Enterprise Value | €95.72m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 10.05 |
P/S ratio (TTM) P/S ratio | 12.29 |
P/B ratio (TTM) P/B ratio | 2.84 |
Revenue growth (TTM) Revenue growth | -13.20% |
Revenue (TTM) Revenue | €9.52m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Heidelberg Pharma:
1 Analyst has issued a forecast Heidelberg Pharma:
May '24 |
+/-
%
|
||
Revenue | 9.52 9.52 |
13%
13%
|
|
Gross Profit | 7 7 |
-
|
|
EBITDA | -21 -21 |
20%
20%
|
EBIT (Operating Income) EBIT | -22 -22 |
20%
20%
|
Net Profit | -13 -13 |
52%
52%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Heidelberg Pharma AG is a holding company, which engages in the development of diagnostic and therapeutic oncology products for the detection and targeted treatment of various types of cancer. It operates through the following segments: Customer Specific Research, Diagnostics, and Therapeutics. The company was founded by Olaf G. Wilhelm, Manfred Schmitt, Viktor Magdolen, Heinrich Graeff, Bernd Gänsbacher, Horst Kessler, Peter Nawroth, and Thomas Luther in September 1997 and is headquartered in Ladenburg, Germany.
Head office | Germany |
CEO | Andreas Pahl |
Employees | 105 |
Founded | 1997 |
Website | heidelberg-pharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.